Invex Therapeutics operational and corporate update

Invex Therapeutics Ltd (ASX:IXC) has released its September Quarterly Activities Report and Appendix 4C, providing an operational and corporate update. The biopharmaceutical company has entered into a new Research Collaboration with Tessara Therapeutics to explore the potential of Exenatide in preventing cell death through disease-relevant pathways. Additionally, the company has received the final report summaries for the IIH EVOLVE Phase III Idiopathic Intracranial Hypertension clinical trial and continues to assess corporate partnerships to complement its existing intellectual property assets within the neurological field.

Executive commentary on research collaboration and corporate development

The research collaboration with Tessara Therapeutics marks a significant step in our efforts to explore the potential of Exenatide in preventing cell death in neurological conditions. We are optimistic about the emerging evidence suggesting that GLP-1 receptor agonists may protect against AD dementia, and we believe that the results from this collaboration will provide important new insights into the role of Exenatide in neurodegenerative diseases. Furthermore, the closure of the IIH EVOLVE Phase III clinical trial and our ongoing assessment of corporate partnerships demonstrate our commitment to advancing our research and expanding our intellectual property assets.

Summary of Invex Therapeutics' operational and corporate update

Invex Therapeutics (ASX:IXC) has made significant progress in its operational and corporate activities, including entering into a research collaboration with Tessara Therapeutics to explore the potential of Exenatide in preventing cell death in neurological conditions. The company has also received the final report summaries for the IIH EVOLVE Phase III clinical trial and continues to assess corporate partnerships to complement its existing intellectual property assets. With a prudent management of its cash reserves and a focus on R&D activities, Invex closed the quarter with cash and cash equivalents of $5.9 million. The company remains optimistic about the potential of Exenatide and is committed to advancing its research in the field of neurological conditions.